158 related articles for article (PubMed ID: 31721608)
21. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer.
Li Y; Sarkar FH
Int J Biol Sci; 2016; 12(3):326-37. PubMed ID: 26929739
[TBL] [Abstract][Full Text] [Related]
22. Functional and Potential Therapeutic Implication of MicroRNAs in Pancreatic Cancer.
Pal A; Ojha A; Ju J
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139352
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
24. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer.
Qian X; Xu W; Xu J; Shi Q; Li J; Weng Y; Jiang Z; Feng L; Wang X; Zhou J; Jin H
Oncotarget; 2017 Jul; 8(29):47691-47708. PubMed ID: 28548950
[TBL] [Abstract][Full Text] [Related]
25. An eight-miRNA signature expression-based risk scoring system for prediction of survival in pancreatic adenocarcinoma.
Dou D; Yang S; Lin Y; Zhang J
Cancer Biomark; 2018; 23(1):79-93. PubMed ID: 29991127
[TBL] [Abstract][Full Text] [Related]
26. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
27. Developments in miRNA gene signaling pathways in pancreatic cancer.
Vorvis C; Koutsioumpa M; Iliopoulos D
Future Oncol; 2016 May; 12(9):1135-50. PubMed ID: 26984178
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
29. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
Wang YW; Zhang W; Ma R
Oncol Rep; 2018 Mar; 39(3):1003-1010. PubMed ID: 29328395
[TBL] [Abstract][Full Text] [Related]
30. MicroRNAs in gastrointestinal cancer: prognostic significance and potential role in chemoresistance.
Hong L; Han Y; Yang J; Zhang H; Zhao Q; Wu K; Fan D
Expert Opin Biol Ther; 2014 Aug; 14(8):1103-11. PubMed ID: 24707835
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
32. Investigating the regulatory role of miRNAs as silent conductors in the management of pathogenesis and therapeutic resistance of pancreatic cancer.
Abulsoud AI; Elshaer SS; Abdelmaksoud NM; Zaki MB; El-Mahdy HA; Ismail A; Al-Noshokaty TM; Fathi D; Abdel-Reheim MA; Mohammed OA; Doghish AS
Pathol Res Pract; 2023 Nov; 251():154855. PubMed ID: 37806169
[TBL] [Abstract][Full Text] [Related]
33. [Diagnosis, treatment and prognosis evaluation of pancreatic cancer by microRNA].
Ren H; Wang CF
Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):903-906. PubMed ID: 33256299
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
35. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.
Zhou X; Lu Z; Wang T; Huang Z; Zhu W; Miao Y
Gene; 2018 Oct; 673():181-193. PubMed ID: 29913239
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA aberrations: An emerging field for gallbladder cancer management.
Chandra V; Kim JJ; Mittal B; Rai R
World J Gastroenterol; 2016 Feb; 22(5):1787-99. PubMed ID: 26855538
[TBL] [Abstract][Full Text] [Related]
37. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer.
Ranade AR; Cherba D; Sridhar S; Richardson P; Webb C; Paripati A; Bowles B; Weiss GJ
J Thorac Oncol; 2010 Aug; 5(8):1273-8. PubMed ID: 20548249
[TBL] [Abstract][Full Text] [Related]
39. Noncoding RNAs in drug-resistant pancreatic cancer: A review.
Lin Z; Lu S; Xie X; Yi X; Huang H
Biomed Pharmacother; 2020 Nov; 131():110768. PubMed ID: 33152930
[TBL] [Abstract][Full Text] [Related]
40. MicroRNAs as potential therapeutic targets for pancreatic cancer.
Chu X; Wei D; Liu X; Long D; Tian X; Yang Y
Chin Med J (Engl); 2022 Jan; 135(1):4-10. PubMed ID: 34839317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
